Jazz Pharmaceuticals (JAZZ) Receivables: 2009-2025
Historic Receivables for Jazz Pharmaceuticals (JAZZ) over the last 16 years, with Sep 2025 value amounting to $764.4 million.
- Jazz Pharmaceuticals' Receivables rose 5.63% to $764.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.8 billion, marking a year-over-year increase of 0.48%. This contributed to the annual value of $716.8 million for FY2024, which is 1.55% up from last year.
- Jazz Pharmaceuticals' Receivables amounted to $764.4 million in Q3 2025, which was up 7.05% from $714.0 million recorded in Q2 2025.
- Jazz Pharmaceuticals' 5-year Receivables high stood at $764.4 million for Q3 2025, and its period low was $414.0 million during Q1 2021.
- In the last 3 years, Jazz Pharmaceuticals' Receivables had a median value of $705.8 million in 2023 and averaged $685.9 million.
- Per our database at Business Quant, Jazz Pharmaceuticals' Receivables spiked by 43.97% in 2021 and then declined by 7.65% in 2025.
- Jazz Pharmaceuticals' Receivables (Quarterly) stood at $563.4 million in 2021, then rose by 15.64% to $651.5 million in 2022, then rose by 8.33% to $705.8 million in 2023, then rose by 1.55% to $716.8 million in 2024, then climbed by 5.63% to $764.4 million in 2025.
- Its last three reported values are $764.4 million in Q3 2025, $714.0 million for Q2 2025, and $653.0 million during Q1 2025.